Oncotarget

Research Papers:

MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2

Hongzhan Liao, Yifeng Bai, Shengcong Qiu, Lei Zheng, Lianyan Huang, Tianzhu Liu, Xin Wang, Yanting Liu, Ningbo Xu, Xiaohui Yan and Hongbo Guo _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2015; 6:8914-8928. https://doi.org/10.18632/oncotarget.3563

Metrics: PDF 2434 views  |   HTML 1706 views  |   ?  


Abstract

Hongzhan Liao1,*, Yifeng Bai2,*, Shengcong Qiu1, Lei Zheng3, Lianyan Huang4, Tianzhu Liu1, Xin Wang1, Yanting Liu1, Ningbo Xu1, Xiaohui Yan5 and Hongbo Guo1

1 Department of Neurosurgery, Neurosurgery Institute of Guangdong, Key Laboratory on Brain Function Repair and Regeneration of Guangdong, Zhujiang Hospital, Southern Medical University, Guangzhou, China

2 Department of Oncology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China

3 Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China

4 School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China

5 Research Center of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China

* These authors contributed equally to this work

Correspondence to:

Hongbo Guo, email:

Keywords: chemotherapy resistance, epithelial-mesenchymal transition, microRNAs, glioblastoma, SNAI2

Received: January 16, 2015 Accepted: February 10, 2015 Published: March 12, 2015

Abstract

Epithelial-mesenchymal transition (EMT) has been recognized as a key element of cell migration, invasion, and drug resistance in several types of cancer. In this study, our aim was to clarify microRNAs (miRNAs)-related mechanisms underlying EMT followed by acquired resistance to chemotherapy in glioblastoma (GBM). We used multiple methods to achieve our goal including microarray analysis, qRT-PCR, western blotting analysis, loss/gain-of-function analysis, luciferase assays, drug sensitivity assays, wound-healing assay and invasion assay. We found that miR-203 expression was significantly lower in imatinib-resistant GBM cells (U251AR, U87AR) that underwent EMT than in their parental cells (U251, U87). Ectopic expression of miR-203 with miRNA mimics effectively reversed EMT in U251AR and U87AR cells, and sensitized them to chemotherapy, whereas inhibition of miR-203 in the sensitive lines with antisense oligonucleotides induced EMT and conferred chemoresistance. SNAI2 was identified as a direct target gene of miR-203. The knockdown of SNAI2 by short hairpin RNA (shRNA) inhibited EMT and drug resistance. In GBM patients, miR-203 expression was inversely related to SNAI2 expression, and those tumors with low expression of miR-203 experienced poorer clinical outcomes. Our findings indicate that re-expression of miR-203 or targeting SNAI2 might serve as potential therapeutic approaches to overcome chemotherapy resistance in GBM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3563